Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook [Yahoo! Finance]
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
Enlivex Therapeutics (ENLV) had its price target raised by HC Wainwright from $13.00 to $20.00. They now have a "buy" rating on the stock.
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt